UBS Keeps "Buy" Rating on InnoCare Pharma with HK$21.80 Target Price

Deep News

09/27

UBS has released a research report maintaining its "Buy" rating and HK$21.80 target price for InnoCare Pharma (09969).

InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.

The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.

According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1191016793"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191016793\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191016793?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-27 12:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191016793","market":"sg","top_or_hot":-1,"title":"UBS Keeps \"Buy\" Rating on InnoCare Pharma with HK$21.80 Target Price","media":"Deep News","content":"<p>UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for <b>InnoCare Pharma (09969)</b>.<br><br>InnoCare Pharma has entered into a collaboration with <b>Eli Lilly (LLY.US)</b> to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.<br><br>The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.<br><br>According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Keeps \"Buy\" Rating on InnoCare Pharma with HK$21.80 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Keeps \"Buy\" Rating on InnoCare Pharma with HK$21.80 Target Price\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time smaller\">2026-09-27 12:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for <b>InnoCare Pharma (09969)</b>.<br><br>InnoCare Pharma has entered into a collaboration with <b>Eli Lilly (LLY.US)</b> to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.<br><br>The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.<br><br>According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物醫藥B類股","start_time":0,"source_url":"","article_id":"1191016793","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191016793","pubTimestamp":1790483430,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for InnoCare Pharma (09969).InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK1574":"生物医药B类股","09969":"诺诚健华","BK0239":"医药制造","EWH":"香港ETF-iShares MSCI","BK1161":"生物科技"},"translate_title":"瑞银维持诺诚健华“买入”评级，目标价21.80港元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"EWH":1,"09969":1},"content_text":"UBS has released a research report maintaining its \"Buy\" rating and HK$21.80 target price for InnoCare Pharma (09969).InnoCare Pharma has entered into a collaboration with Eli Lilly (LLY.US) to discover and develop up to five innovative target projects. The investment bank views this positively, considering it a recognition of the company's research and development capabilities.The bank noted that the upfront payment and near-term milestone payments total US$100 million, with potential development and commercial milestone payments reaching US$3.25 billion, along with tiered royalties in the single-digit percentage range on net sales.According to management, all projects will begin from the drug discovery stage. The related payments could bring upside potential to revenue and net profit in 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}